MNNIT, KGMU develop device to reduce repetitive X-rays after bone fracture
Tired of too many ads? go ad free now
This fibre optics-based sensing device provides information regarding changes in the pattern of the optical spectrum generated by the device, revealing detailed information about the strength of the bone's recovery.
Another advantage of this sensor-based device is that it will save patients from the adverse effects of radiation, as doctors will not need to take repetitive X-rays to evaluate the recovery progress of the broken bone.
The device is the result of efforts of assistant professor at the department of applied mechanics of MNNIT, Abhishek Kumar Tiwari, along with Prof Yogendra Kumar of the electronics and communication (ECE) branch, Dr Ravindra Mohan of KGMU's bone surgery department, and researchers Rishabh Singh and Archana.
Anusandhan National Research Foundation (ANRF) gave a grant of Rs 49 lakh in 2023, following which the device was developed by these experts.
"This device is based on optical sensing, which works with the help of sensors and computational models. After the doctor applies the plaster or fixator, the sensor-based device is installed on the outer part of the body (say fixator), which collects information related to the vibration and strength of the bone.
When the patient exerts pressure, the sensors study the changes in the optical spectrum, based on which the doctor can easily determine how much the bone has recovered," said Tiwari.
Tired of too many ads? go ad free now
Researchers claim that this technology will prove to be extremely useful, especially in places where X-ray machines are not available or where protection from radiation is required.
"When the patient is diagnosed with a broken bone through an X-ray film, the doctor either applies a plaster or fixator, and the patient has to return for repetitive X-rays to assess the recovery of the broken bone. But, if the device is used, the doctor can assess the recovery of the bone without the X-ray," explained Tiwari.It will be especially useful for pregnant women, children, or cancer patients, as they will not have to undergo repetitive X-rays, he added.
In the initial phase of testing, this device was successful in providing accurate information.
"This technology can prove to be revolutionary for the health of the patient, as given the sensitivity and accuracy of the device, the patient does not have to get repetitive X-rays," said Abhishek Tiwari.
Prayagraj: Experts from Motilal Nehru National Institute of Technology (MNNIT), Prayagraj, and King George Medical University (KGMU), Lucknow, have jointly developed a device that will reduce the number of repetitive X-rays doctors take to check the recovery of broken bones after applying a plaster or fixator.
This fibre optics-based sensing device provides information regarding changes in the pattern of the optical spectrum generated by the device, revealing detailed information about the strength of the bone's recovery.
Another advantage of this sensor-based device is that it will save patients from the adverse effects of radiation, as doctors will not need to take repetitive X-rays to evaluate the recovery progress of the broken bone.
The device is the result of efforts of assistant professor at the department of applied mechanics of MNNIT, Abhishek Kumar Tiwari, along with Prof Yogendra Kumar of the electronics and communication (ECE) branch, Dr Ravindra Mohan of KGMU's bone surgery department, and researchers Rishabh Singh and Archana.
Anusandhan National Research Foundation (ANRF) gave a grant of Rs 49 lakh in 2023, following which the device was developed by these experts.
"This device is based on optical sensing, which works with the help of sensors and computational models. After the doctor applies the plaster or fixator, the sensor-based device is installed on the outer part of the body (say fixator), which collects information related to the vibration and strength of the bone.
When the patient exerts pressure, the sensors study the changes in the optical spectrum, based on which the doctor can easily determine how much the bone has recovered," said Tiwari.
Researchers claim that this technology will prove to be extremely useful, especially in places where X-ray machines are not available or where protection from radiation is required.
"When the patient is diagnosed with a broken bone through an X-ray film, the doctor either applies a plaster or fixator, and the patient has to return for repetitive X-rays to assess the recovery of the broken bone. But, if the device is used, the doctor can assess the recovery of the bone without the X-ray," explained Tiwari.It will be especially useful for pregnant women, children, or cancer patients, as they will not have to undergo repetitive X-rays, he added.
In the initial phase of testing, this device was successful in providing accurate information.
"This technology can prove to be revolutionary for the health of the patient, as given the sensitivity and accuracy of the device, the patient does not have to get repetitive X-rays," said Abhishek Tiwari.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hans India
4 hours ago
- Hans India
India's 1st animal stem cell biobank, lab to boost regenerative medicine & therapies for livestock
New Delhi: India on Saturday got the first animal stem cell biobank and animal stem cell laboratory that will focus on regenerative medicine and therapies for livestock. Inaugurated by Union Minister of State (Independent Charge) Science & Technology, Dr. Jitendra Singh, the biobank and lab is situated at the National Institute of Animal Biotechnology (NIAB), Hyderabad. The cutting-edge facility of Animal BioBank is spread over 9,300 sq ft and has been constructed at a cost of RS 1.85 crore. The laboratory is equipped with a stem cell culture unit, 3D bioprinter, bacterial culture lab, cryostorage, autoclave rooms, advanced air handling systems, and uninterrupted power backup. It will advance research in disease modelling, tissue engineering, and reproductive biotechnology. With support from the National Biopharma Mission (NBM) of DBT–BIRAC, the facility will be expanded to enable biobanking of animal stem cells and their derivatives. 'We had such facilities for human stem cells, but hardly any for animal cells. The best of NIAB, and the best of Indian biotechnology, is yet to come,' Singh said, adding that these facilities will contribute "to making India future-ready". 'We will not lag behind when the next industrial revolution—driven by biotechnology—takes over. The economy will shift from manufacturing to regenerative and genetic processes, and India has already initiated this transition,' he added. The Minister also laid the foundation stone of a new hostel block and Type-IV quarters at NIAB, approved by the Department of Biotechnology at a total cost of Rs 19.98 crore. The infrastructure will cater to the needs of research scholars, faculty, and staff, fostering a vibrant academic and innovation ecosystem. In addition, Singh launched innovative veterinary diagnostic tools designed to revolutionise animal health management and support the 'One Health' approach. These include a field-deployable, DIVA-capable diagnostic kit for early and accurate detection of Brucella species; a cost-effective on-site diagnostic assay for subclinical and clinical mastitis in dairy cattle; a portable antimicrobial sensitivity testing device providing results within two hours to promote responsible antibiotic use; a sensitive and specific test for Toxoplasma gondii infection in animals; an indigenously developed rapid strip for large-scale surveillance of Japanese Encephalitis in animals and humans. 'These innovations will boost agriculture-linked GDP, enhance livestock productivity, and pave the way for an 'Evergreen Revolution' in the animal husbandry sector,' the Minister emphasised. On the agricultural front, 'these releases mark a new phase of animal-based agricultural productivity -- an 'Evergreen Revolution'. With 18 per cent of GDP from agriculture and 60 per cent of our workforce depending on it, innovations in veterinary health will have a transformative impact,' he said. 'One rupee spent on agricultural research yields a return of Rs 13, and linking industry partners from day one ensures these technologies reach the ground,' Singh added.
NDTV
6 hours ago
- NDTV
BPSC Invites Application For 590 Principal, Associate Professors Posts In Engineering, Polytechnic Colleges
BPSC Associate Professor, Principal Recruitment 2025: The Bihar Public Service Commission (BPSC) has invited applications for the post of 590 Principal and Associate Professors in government engineering, polytechnic Institutes under Science, Technical and Technology department. Interested candidates can check the notification on the official website of the commission, The online applications for the post of Principal in polytechnic institutes will begin on August 12 and end on September 9, 2025. For the post of Assistant Professor, candidates will be able to apply online starting August 12, till September 12, 2025. BPSC Teacher, Principal Recruitment 2025: Number of Vacancies Available Of the total 590 vacancies, 539 vacancies have been invited for Assistant Professor under various departments such as Civil Engineering, Mechanical Engineering, Electrical Engineering and more. Principal (Engineering) vacancies include 25 under Science, Technology and Technical Education department. For the post of Polytechnical principals, 26 vacancies have been invited under various departments including Computer Science and Engineering, Electrics and Communication Engineering and Electrical and Electronics Engineering. BPSC Recruitment 2025: Eligibility Criteria Candidate applying must be 30 and 37 years of minimum age to be eligible to apply for the post of Associate Professor and Principal. The BPSC has not specified any maximum age limit for any of the posts. Candidates are required to pay the fees based on their category: 100 rupees for General category candidates, Rs. 25 for Scheduled Caste/Scheduled Tribes (SC/ST), all female candidates who are permanent residents of Bihar, Handicapped candidates. All other candidates will be required to pay a fee of Rs. 100. Candidates must fill the application form online and must make sure they meet all the eligibility requirements.
Business Standard
7 hours ago
- Business Standard
Shilpa Medicare gets Shilpa Medicare approval for novel NAFLD drug NorUDCA
Shilpa Medicare has announced the receipt of approval of its, Nor Ursodeoxycholic Acid (NorUDCA) Tablets 500 mg, by the Central Drugs Standard Control Organization (CDSCO), marking a major milestone in innovative NAFLD therapy in India. The approval reinforces Shilpa Medicares commitment to addressing unmet medical needs in hepatology through innovation and evidence‐based solutions. This approval will allow Shilpa to become the first company in the World to launch this novel product in any part of the World for NAFLD. NorUDCA is the first‐in‐class treatment for non‐alcoholic fatty liver disease (NAFLD) in India, addressing a significant unmet medical need. NAFLD is currently the most prevalent liver condition globally, affecting about 25% of the worlds population (approximately 1.2 billion people) and impacting an estimated 188 million individuals in India alone. If not managed early, NAFLD may progress to non‐alcoholic steatohepatitis (NASH) and severe liver complications, underscoring the urgent necessity for effective therapy. These results collectively demonstrate a significant improvement in both liver structure and function, confirming NorUDCAs superior efficacy compared to placebo in NAFLD. Vishnukant Bhutada, managing director, Shilpa Medicare, said: "We are delighted to receive historic approval for NorUDCA, Indias first‐in‐class therapy for NAFLDmaking Shilpa the first company globally to obtain approval for NorUDCA in this indication. This milestone is a moment of immense pride for Shilpa and the nation, as we now pioneer the launch of its finished dosage form. This breakthrough exemplifies Shilpas unwavering dedication to innovation and accessible healthcare to millions battling liver disease in India and beyond. We are excited to introduce NorUDCA tabletsin India immediately, while advancing global regulatory efforts to bring this vital therapy to patients internationally. Shilpa Medicare is a manufacturer of API, formulation, and development services. Shilpa Medicare (SML) started its operations as an API manufacturer way back in 1987 at Raichur, Karnataka, India. The company's consolidated net profit fell 40.77% to Rs 14.51 crore, while revenue from operations rose 13.40% to Rs 330.80 crore in Q4 FY25 over Q4 FY24. The scrip had advanced 1.46% to end at Rs 831.80 on the BSE on Friday.
